2017 Press Releases

 

May 22, 2018 Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action
The National Institute on Aging (NIA) of the National Institutes of Health (NIH) have awarded Cognition $6.6 million in grants, which will fund the SNAP (COG0104) and SPARC (COG0105) studies, both of which are expected to start in mid-2018.
March 14, 2018 Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting
Dr. Susan Catalano will make a presentation during a late-breaking symposium at the joint AAT-AD/PD meeting highlighting Elayta’s effect on biomarkers of synaptic degeneration and its synaptoprotective mechanism of action…
March 6, 2018 Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting
Dr. Susan Catalano, Cognition’s co-founder and chief science officer, will make an oral presentation at the annual meeting of the American Society of Experimental Neurotherapeutics (ASENT) detailing results from the Elayta (CT1812) Phase 1b/2a clinical study in mild-to-moderate Alzheimer’s disease patients. These results demonstrate Elayta’s unique synaptoprotective mechanism of action…
January 12, 2018 Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference
President & CEO Kenneth I. Moch will be hosting one-on-one meetings with select institutional investors at the Leerink Partners 7th Annual Global Healthcare Conference at the Lotte New York Palace Hotel in New York, NY from February 14-15th, 2018. During his meetings, Mr. Moch will provide an overview of the company´s strategy as well as an update on its development program for Elayta™ (CT1812)…
January 4, 2018 Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum
Cognition Therapeutics, Inc. announced that Dr. Susan Catalano, Cognition’s co-founder and chief science officer, will make two presentations at the upcoming Sachs Associates Neuroscience Innovation Forum on January 7, 2018. Dr. Catalano will be participating on a panel titled “Advances in Alzheimer’s and other Cognitive Disorders” at 10:25am PT, and will separately make a corporate presentation at 3:20pm PT.
November 8, 2017 Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference
Cognition Therapeutics, Inc. announced that President & CEO Kenneth I. Moch will present at the Stifel 2017 Healthcare Conference at 8:45 a.m. on November 15, 2017 at the Lotte New York Palace Hotel. Mr. Moch’s presentation will include a corporate update as well as summary of results from the company’s Phase 1b/2a study of CT1812…
November 4, 2017 Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery
Cognition Therapeutics, Inc. announced the results of a randomized, multi-dose, placebo-controlled Phase 1b/2a clinical study (COG0102) of CT1812. All three CT1812 doses were well tolerated; all adverse events were mild or moderate…
October 30, 2017 Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th
Cognition Therapeutics, Inc. announced that the biomarker and clinical results from the recently completed Phase 1b/2a clinical study (COG0102) of CT1812 will be presented in a Late-Breaking Poster and Late-Breaking Oral Communication at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) meeting…
October 24, 2017 Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate
Cognition Therapeutics, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued a composition of matter patent (No. 9,796,672) for CT1812, Cognition’s first-in-class, orally available Alzheimer’s disease drug candidate…
October 16, 2017 Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812
Cognition Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug CT1812 for the treatment of patients with Alzheimer’s disease. Fast Track designation is a process to facilitate the development and expedite the FDA review of new drugs that are intended to treat serious or life-threatening conditions and that address an unmet medical need…
September 20, 2017 Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference
Cognition Therapeutics, Inc. President & CEO Kenneth I. Moch will will present at the Ladenburg Thalmann 2017 Healthcare Conference at 9:00 a.m. on September 26, 2017 at the Sofitel New York Hotel. Mr. Moch’s presentation will include a corporate update as well as a discussion of CT1812, the company’s small molecule drug candidate for the treatment of mild-to-moderate Alzheimer’s disease…
September 7, 2017 Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day
Cognition Therapeutics, Inc. President & CEO Kenneth I. Moch will participate in the Mizuho Biotechnology Conference: CNS Deep Management Day on September 19, 2017 at the Langham Boston Hotel. The clinical status of Cognition’s small molecule drug candidate, CT1812, will be among topics discussed by Mr. Moch. Patient dosing and follow-up has concluded in a Phase 1b/2 clinical study…
August 23, 2017 Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting
Cognition Therapeutics, Inc. today announced that an oral presentation had been made at the ACS National Meeting highlighting the company’s phenotypic neuronal assay that has been successful at identifying orally available, highly brain-penetrant small molecule drug candidates for Alzheimer’s and other neurological diseases…
August 2, 2017 Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors
Cognition Therapeutics, Inc. today announced that Stephen Sands has joined the Company’s Board of Directors. Mr. Sands, the Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group at Lazard, has built a 25-year career providing strategic and financial advice to senior executives and boards of directors at leading healthcare and life sciences companies globally…
July 31, 2017 Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference
Cognition Therapeutics, Inc. announced that President & CEO Kenneth I. Moch will present a corporate and clinical update at the Canaccord Genuity Annual Growth Conference on August 10, 2017 at 1:00pm ET at the InterContinental Hotel in Boston, MA. A live and archived webcast of the presentation will be available on the company’s events webpage…
July 19, 2017 Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate
Cognition Therapeutics, Inc. today presented results of an open-label Phase 1 study of Cognition’s lead clinical candidate, CT1812. In this study, which was presented at the Alzheimer’s Association International Conference in London, no clinically significant drug-drug interactions were identified with CT1812…
April 3, 2017 Cognition Therapeutics CEO Kenneth I. Moch Presenting at BioCentury Future Leaders Conference
Cognition Therapeutics, Inc. announced that the company has been selected to present at the annual Future Leaders in the Biotech Industry conference hosted by BioCentury. Kenneth I. Moch, president & CEO of Cognition will present an update on corporate milestones and development status of CT1812, the company’s lead candidate for the treatment of Alzheimer’s disease…

 

View Press Release Archive